Overview

A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

To further assess the safety and effectiveness of adalimumab 40mg in the treatment PsA who have had an unsatisfactory response or intolerance to prior or ongoing DMARDs

Phase:

Phase 3

Details

Lead Sponsor:

Abbott

Treatments:

Adalimumab